Temperature-Sensing MRI could sharpen prostate cancer detection
NCT ID NCT04822272
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new MRI method that measures temperature changes in the prostate. The goal is to help doctors find cancer more accurately and guide laser treatments. Researchers scanned 70 men who already needed an MRI for prostate cancer diagnosis. The focus was on checking if the temperature readings were clear and reliable.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- MRI thermometry
- What this could lead to
- If successful, this technique could help doctors better detect prostate cancer and guide targeted laser treatments with less side effects.
- What could go wrong
- This was a small, early-stage study focused on measuring temperature accuracy, not on treating cancer. The technique may not improve diagnosis or treatment outcomes in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
70 people
The number who actually took part.
- Started
-
Jul 2022
- Finished
-
Jun 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years old * Patient with indication of injected multi-parameter MRI for the diagnosis of prostate cancer. * Signed informed consent. * Person affiliated or beneficiary of health insurance Exclusion Criteria: * MRI contraindications (Pace Maker, metallic foreign body, metallic heart valve). * Contraindication to gadolinium salt, * Patient under legal protection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Bordeaux
Bordeaux, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive missile aims at prostate cancer that spread
- New PET tracer targets ACP3 to spot prostate cancer
- Can a One-Week radiation course match four weeks for prostate cancer?
- Can a new PET tracer spot hidden prostate cancer spread?
- Can a gel cushion shield the rectum during prostate radiation?
- A scanner in the operating room could show surgeons exactly where prostate cancer remains